New developments in the management of moderate-to-severe hemophilia B
about
Once-weekly prophylactic dosing of recombinant factor IX improves adherence in hemophilia BSystemic delivery of factor IX messenger RNA for protein replacement therapyProduction of recombinant coagulation factors: Are humans the best host cells?Nonacog Beta Pegol: A Review in Haemophilia B.Extended Half-Life Factor VIII and Factor IX Preparations.
P2860
New developments in the management of moderate-to-severe hemophilia B
description
2016 nî lūn-bûn
@nan
2016 թուականին հրատարակուած գիտական յօդուած
@hyw
2016 թվականին հրատարակված գիտական հոդված
@hy
2016年の論文
@ja
2016年論文
@yue
2016年論文
@zh-hant
2016年論文
@zh-hk
2016年論文
@zh-mo
2016年論文
@zh-tw
2016年论文
@wuu
name
New developments in the management of moderate-to-severe hemophilia B
@ast
New developments in the management of moderate-to-severe hemophilia B
@en
New developments in the management of moderate-to-severe hemophilia B
@nl
type
label
New developments in the management of moderate-to-severe hemophilia B
@ast
New developments in the management of moderate-to-severe hemophilia B
@en
New developments in the management of moderate-to-severe hemophilia B
@nl
prefLabel
New developments in the management of moderate-to-severe hemophilia B
@ast
New developments in the management of moderate-to-severe hemophilia B
@en
New developments in the management of moderate-to-severe hemophilia B
@nl
P2860
P3181
P356
P1476
New developments in the management of moderate-to-severe hemophilia B
@en
P2093
Moniba Nazeef
P2860
P3181
P356
10.2147/JBM.S81520
P407
P50
P577
2016-01-01T00:00:00Z